Haemonetics Q3 2026 Earnings Call Transcript: Strong Quarter, Raised Guidance
ByAinvest
Friday, Feb 6, 2026 6:13 pm ET1min read
HAE--
Haemonetics reported Q3 2026 revenue of $339 million, with underlying organic growth of 8% ex-CSL. Adjusted EPS increased 10% to $1.31, driven by strong performance in Blood Management Technologies, which grew 8% in the quarter and 11% year-to-date. The company raised full-year revenue, earnings, and free cash flow guidance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet